Skip to content

Effect of Flixweed and Fig on Irritable Bowel Syndrome With Predominant Constipation: a Single Blind Randomized Clinical Trial.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02559245
Enrollment
150
Registered
2015-09-24
Start date
2015-09-30
Completion date
2016-01-31
Last updated
2018-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome Predominant Constipation

Brief summary

This study evaluates effect of Ficus carica and Descurainia Sophia on irritable bowel syndrome predominant constipation. one-third of patients will receive Ficus carica, another one-third will receive Descurainia Sophia and remained patients only will follow their regular diet for 4 months.

Interventions

OTHERFicus carica
OTHERDescurainia Sophia

Sponsors

Isfahan University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* patients with irritable bowel syndrome predominant constipation

Exclusion criteria

* Subjects with significant cardiovascular, renal, hepatic, pulmonary, endocrine, metabolic, hematologic disorders, * structural abnormalities of the gastrointestinal tract or * diseases ⁄conditions that affected bowel transition, * surgery, * any prokinetic or laxative drug used during the past month, * any medication that may affect gastrointestinal motility, * other therapeutic dietary advice for IBS, * used Fig or Flixweed during the last month, * diarrhea, * pregnancy or * breast-feeding

Design outcomes

Primary

MeasureTime frameDescription
irritable bowel syndrome constipation predominant symptom4 monthsIBS severity score system questionnaires will use for evaluation of IBS-C symptoms at the pre and post-intervention. This tool is validated for use in IBS patients that assess 5 clinically relevant items during past 10-days and including severity of abdominal pain, frequency of abdominal pain, severity of abdominal distention, dissatisfaction with bowel movement and interference of IBS with life in general. Each items was scored with a 100 mm visual analogue scale (VAS).

Secondary

MeasureTime frameDescription
quality of life in IBS-C patients4 monthsquality of life in IBS-C patients were assessed at pre-and post-intervention using a self-report Irritable Bowel Syndrome-Quality of Life Measure (IBS-QoL). It contains 34 items with 8 sub-classification including dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual, and relationships. The sum of response to this items by every subject were average and transform to 0-100 scale. The higher score indicated better quality of life among IBS-C patients.
frequency of defecation and hard stool4 monthsfrequency of defecation and hard stool was evaluated at baseline and end of every month using the visual analogue scale (VAS)

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026